Файловый архив студентов. Файловый архив студентов.
1327 вузов, 5482 предметов.
/ Регистрация
FAQ Обратная связь Вопросы и предложения
Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Ростовский Государственный Медицинский Университет
Предмет:
Медицина общая
Файл:

Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_1109_Библиотеки_им_академика_М_И_Перельмана

.pdf
Скачиваний:
0
Добавлен:
02.09.2026
Размер:
20 Мб
Скачать
☆
124
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
O. N. Dilek and N. Acar
Since both entities are quite rare, PC for their asymptomatic onset is not well established. Nevertheless, the removal of the additional section during the index surgery should not be forgotten in order to avoid recurrence [119]. Hourglass shaped can be seen with adenomyomatosis of gallbladder, and PC is recommended due to the high cancer risk of adenomyomatosis [120].
11.2.11 Carrier forBacterial Agents
Salmonella Typhi (S. Typhi) and Salmonella Paratyphi A (S.Paratyphi A) which are the bac-
terial agents of enteric fever can stay asymp­tomatic in gallbladder in 2–5% of the infected individuals [121]. These patients, which are dened as carriers, may not manifest any signs of disease, but still spread the bacteria by its fecal–oral route. Chronic carriage for S.Typhi is also related with gallbladder cancer due to chronic inammation [122]. PC is a feasible approach when carriage for S. Typhi is con­rmed in order to prevent both the spread of the infectious disease and the malignant trans­formation. However, it was also reported that cholecystectomy may not certainly eradicate the disease since the bacterial colonization can persist even in biliary tract, mesenteric lymph nodes, and liver [123].
11.3 Biliary Tract
Conditions of the biliary tract requiring pro­phylactic surgery are mostly related with the conditions requiring PC. Various preneoplas­tic pathologies may occur as a result of chronic inammation and mucosal damage resulting from some congenital or acquired pathologies of the biliary tract. In this part, some preneoplastic and non-neoplastic conditions are going to be briey re-mentioned as well as the conditions specic to biliary tract are going to be explained in detail.
11.3.1 Pancreaticobiliary
Maljunction
Pancreaticobiliary maljunction leads to biliary duct cancer, with the previously mentioned mech­anism, in 3.1–4% and 6.9–11% of the patients without and with biliary dilatation, respectively [84, 85]. Therefore, bile duct dilatation is the key point to determine the treatment approach. In cases with dilated bile duct, complete excision of the dilated extrahepatic bile ducts in addition to PC is recommended. Roux- en- Y hepaticojeju­nostomy or end-to-side hepaticoduodenostomy can be performed as the reconstructive tech­niques [124].
On the other hand, treatment approach in cases without biliary dilatation is controversial. Although majority of the studies have advocated that sole PC is adequate for the cases without biliary dilatation since bile duct cancer is not as frequent as gallbladder cancer, some studies have proposed an opposing opinion. Precancerous lesions, which were often not detected with pre­operative imaging, were found in 73% of non­dilated bile duct cancers with pancreaticobiliary maljunction [125]. Additionally, recent studies showed that histological changes on the epithe­lium of non-dilated bile ducts were similar to dilated bile ducts [124, 126]. For these reasons, prophylactic excision of the extrahepatic bile duct is introduced as a reasonable approach by some experts regarding the prevention of car­cinogenesis [87, 124]. However, prophylactic surgery for non-dilated bile duct in pancreatico­biliary maljunction should be evaluated carefully by considering the short- and long-term compli­cations of biliary surgery.
11.3.2 Choledochal Cyst
Choledochal cyst is a rare congenital condition which usually manifests during childhood and rarely in adults. Its incidence was reported as 1:100,000–150,000 in Western populations and 1:1000 in Asian populations. Pancreaticobiliary
11 Prophylactic Surgery forGallbladder andBiliary Tract Pathologies
maljunction is responsible for 50%–80% of the cases [127]. Besides causing cholangitis and pancreatitis episodes, it also carries a risk of malignant transformation just like pancreatico­biliary maljunction. Previous studies have shown that 10–30% of adults with choledochal cysts develop cholangiocarcinoma, and choledochal cysts increase the risk for cholangiocarcinoma 20–30 times higher than general population [128]. A meta-analysis of 18 studies by ten Hove etal. (2018) showed that malignancies may develop in up to 11% of patients with choledochal malfor­mation, and treating choledochal malformation
Fig. 11.4 This picture shows the specimen of a patient with a type 4 choledochal cyst
may prevent developing malignancy. In addition, no differences in the prevalence of malignancy between the different types of choledochal mal­formation were found [129].
ried on in patients with choledochal cysts even after surgical interventions.
Treatment choices vary according to the clas­sication introduced by Todani et al. (1977) [130]. Type I and type IV cysts have higher inci-
11.3.3 Biliary Intraepithelial
dence for cancer, while type II and type III have a lower risk [128, 131]. 68% of cholangiocarci­noma are reported to be associated with type I cysts and 21% with type IV [132]. Therefore, less invasive techniques such as simple excision and endoscopic sphincterotomy are usually adequate for the treatment of type II and type III cysts, respectively, when the possibility of a concurrent cancer can be excluded.
Management of type IVA and V (Caroli’s disease) cysts has been controversial due to the involvement of intrahepatic ducts. Cyst excision and an additional wide hilar hepati­coenterostomy can be performed in type IVA (Fig.11.4). Cancer development is reported in 7–15% of patients with type V cysts (Caroli’s disease) [132]. Hepatic lobectomy inlocalized type V cysts (Caroli’s disease) can be preferred. However, since prophylactic liver transplant is not a feasible approach in asymptomatic cases, close surveillance for cancer development is recommended instead [133].
Despite all these preventive efforts, there is 1% risk of cancer development following the cyst excision [134]. Lifelong follow-up should be car-
Biliary intraepithelial neoplasia (BilIN) develops as a result of chronic inammatory processes such as primary sclerosing cholangitis (PSC), hepatolithiasis, choledoc cyst, chronic hepatitis B and C, and alcoholic cirrhosis. Patients with PSC have a high risk (>160 times) of developing cholangiocellular carcinoma. Cancer develops in
0.5–1.5% of patients with PSC each year, and the risk of developing lifelong cancer is calculated as 15–20% [135]. It was determined that BilIN developed in 10% of cases with hepatolithiasis. BilIN is a precursor lesion of cholangiocarcinoma and represents three different degrees of dysplas­tic changes of the epithelium. Although its prog­nosis is not clear, prophylactic surgical resection with PC should be performed when detected, in order to remove the risk of cholangiocarcinoma at an early stage. Detection of BilIN in surgi­cal margins is an important problem in patients undergoing resection [132, 136].
Patients with Lynch syndrome have an increased risk of developing cholangiocarci­noma. Multiple primary papillomatosis is another
125
Neoplasia (BilIN)
126
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
O. N. Dilek and N. Acar
genetic disease, characterized by precancerous papillomatosis of the mucosa [132].
11.3.4 Intraductal Papillary Neoplasia oftheBile Duct (IPN-B)
Intraductal papillary neoplasia of the bile duct (IPN-B) is another rare entity that constitutes 10–15% of bile duct tumors [137]. It has three subtypes which are thought to be premalignant lesion of cholangiocarcinoma: adenoma, border­line tumor, and carcinoma in situ [87]. Complete surgical excision is the best treatment modality in cases without distant metastasis [138]. Surgical technique depends on the location of the tumor. Since the main goal is to achieve R0 resection, additional hepatectomy or pancreaticoduodenec­tomy should be considered in proximal and dis­tant tumors, respectively.
11.3.5 Locally Invasive Gallbladder Cancer
Malignant cells in gallbladder cancer can spread through lymph vessels in the submucosal layer of the common bile duct, in addition to the large lymph vessels in subserosal layer [139]. With this concept, efcacy of the resection of extra­hepatic bile duct in gallbladder cancer has been researched in many studies. In general, routine resection of the extrahepatic bile duct is not rec­ommended in patients who have no involvement and have a negative cystic duct margin since major hepatic and biliary resections increase morbidity [140, 141]. Sakamoto etal. (2006) pro­posed resection of extrahepatic bile duct when perineural invasion exists, even in the absence of biliary inltration [142]. Chikamoto etal. (2009), on the other hand, advocated en bloc resection of the extrahepatic bile duct in curative resection even for T2 gallbladder cancer due to the lym­phatic spread through submucosal layer [139]. In several different studies, prophylactic extrahe­patic bile duct resection in patients without mac-
roscopic bile duct invasion has shown to have no survival impact [143, 144].
Laparoscopic cholecystectomy is the rst treatment method in patients with cholelithia­sis. However, in cases that are thought to have gallbladder carcinoma; it is recommended to perform surgery with laparotomy in terms of increased risk of port site metastasis (11–16%), gallbladder perforation risk (20%) and associ­ated tumor spread, and presence of invasion and regional lymph tissue dissection [73, 145, 146]. Because of the risk of tumor, specimens should be removed in a special bag.
In 1% of cases undergoing laparoscopic cho­lecystectomy, gall bladder carcinoma is detected. In T1a cases, laparoscopic cholecystectomy is sufcient. The risk of vascular and perineu­ral invasion increases in the lesions reaching the subserosis, and lymph node involvement is detected in approximately half of the cases [147]. In T1b cases, radical cholecystectomy should be performed. For this purpose, partial liver resec­tion and port site resection should be performed, including a tissue 3cm deep from the liver seg­ments 4B and 5. On the contrary, NCCN does not recommend prophylactic port site resection, since it is not associated with improved survival or recurrence [76]. In T2 cases, segment 4B and 5 parts are included in the resection. From the cystic canal stump, sampling is done with fro­zen section. Extrahepatic biliary tract resection and regional lymph node dissection are also per­formed in cases with tumor-positive results [73].
Conditions that require liver resection and vas­cular resection in order to increase survival and success due to biliary tract tumors are described in the relevant section (See Chap. 9; Liver).
Prophylactic surgery of the gallbladder and biliary tract targets to eliminate various risks which eventually impair the quality of life. Since there are still many controversial issues in terms of indications, it is vital to follow actual literature and guidelines on this topic. Biliary tract opera­tions should be performed in centers with high volumes, sufcient technical equipment, and experienced surgeons due to high morbidity and mortality risks.
11 Prophylactic Surgery forGallbladder andBiliary Tract Pathologies
127
11.3.6 Biliary Atresia
It is an idiopathic, progressive, brous obstruc­tive neonatal disease of the biliary tract. The incidence is one in 10–20 thousand births. It is the most common cause of the yellowness of the newborn requiring surgical treatment. It may be accompanied by other organ anomalies and mal­rotations. In the etiology of the disease, viruses, toxins, genetic mutations (CFC1 gene, PKD1L1 gene), and immunological disorders have been blamed [148]. In patients generally diagnosed in the months after birth, bile drainage should be performed rapidly in order to prevent liver damage and cirrhotic process. Roux-en-Y type hepatoportoenterostomy (HPE) is the standard treatment method in the treatment of biliary atre­sia. HPE can be applied with laparoscopic and open surgery. However, complications such as stula and stenosis developing in the early post­operative period are important causes of morbid­ity and mortality [149]. In studies conducted, it is recommended to perform HPE primarily in patients with biliary atresia, since the pre­prophylactic liver transplants to be performed in the early period cannot achieve the desired suc­cess due to technical difculties (See Chap. 9; Liver). Following HPE cases, liver tissue is within normal limits in approximately one-third of the cases after 4years. Approximately half of the cases require liver transplantation due to ste­nosis in the biliary tract or liver failure [150]. It is recommended that corrective restoration attempts in cases with stenosis are not successful, and liver transplantation should be performed due to the growth of children [148].
References
1. Tarantino G, Magistri P, Ballarin R, Assirati G, Di Cataldo A, Di Benedetto F. Surgery in biliary lithia­sis: from the traditional “open” approach to laparos­copy and the “rendezvous” technique. Hepatobiliary Pancreat Dis Int. 2017;16(6):595–601.
2. Nagino M.Fifty-year history of biliary surgery. Ann Gastroenterol Surg. 2019;3(6):598–605.
3. Wang DQ-H, Portincasa P.Gallstones: recent advances in epidemiology, pathogenesis, diagnosis and manage­ment. NewYork: Nova Science; 2017.
4. Ibrahim M, Sarvepalli S, Morris-Stiff G, Rizk M, Bhatt A, Walsh RM, etal. Gallstones: watch and wait, or intervene? Cleve Clin J Med. 2018;85:323–31.
5. Schirmer BD, Winters KL, Edlich RF.Cholelithiasis and cholecystitis. J Long Term Eff Med Implants. 2005;15:329–38.
6. Caddy GR, Kirby J, Kirk SJ, Allen MJ, Moorehead RJ, Tham TC.Natural history of asymptomatic bile duct stones at time of cholecystectomy. Ulster Med J. 2005;74(2):108–12.
7. Shabanzadeh DM. Incidence of gallstone dis­ease and complications. Curr Opin Gastroenterol. 2018;34(2):81–9.
8. Cabarrou P, Portier G, Chalret Du Rieu M. Prophylactic cholecystectomy during abdominal surgery. J Visc Surg. 2013;150(4):229–35.
9. Lee SY, Jang JH, Kim DW, Park J, Oh HK, Ihn MH, et al. Incidental cholecystectomy in patients with asymptomatic gallstones undergoing surgery for colorectal cancer. Dig Surg. 2015;32(3):183–9.
10. Juhasz ES, Wolff BG, Meagher AP, Kluiber RM, Weaver AL, van Heerden JA. Incidental chole­cystectomy during colorectal surgery. Ann Surg. 1994;219(5):467–72; discussion 472–4.
11. Klaus A, Hinder RA, Swain J, Achem SR.Incidental cholecystectomy during laparoscopic antireux sur­gery. Am Surg. 2002;68(7):619–23.
12. Tan Z, Xie P, Qian H, Yao X.Clinical analysis of pro­phylactic cholecystectomy during gastrectomy for gastric cancer patients: a retrospective study of 1753 patients. BMC Surg. 2019;19:48.
13. Sood S, Winn T, Ibrahim S, Gobindram A, Arumugam AA, Razali NC, etal. Natural history of asymptomatic gallstones: differential behaviour in male and female subjects. Med J Malaysia. 2015;70(6):341–5.
14. Murshid KR. Asymptomatic gallstones: should we operate? Saudi J Gastroenterol. 2007;13:57–69.
15. Stinton LM, Shaffer EA.Epidemiology of gallblad­der disease: cholelithiasis and cancer. Gut Liver. 2012;6(2):172–87.
16. Behari A, Kapoor VK. Asymptomatic gall­stones (AsGS)—to treat or not to? Indian J Surg. 2012;74(1):4–12.
17. Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer. 2006;118(7):1591–602.
18. Méndez-Sánchez N, Chavez-Tapia NC, Motola­Kuba D, Sanchez-Lara K, Ponciano-Rodríguez G, Baptista H, etal. Metabolic syndrome as a risk fac­tor for gallstone disease. World J Gastroenterol. 2005;11(11):1653–7.
19. Ikard RW.Gallstones, cholecystitis and diabetes. Surg Gynecol Obstet. 1990;171(6):528–32.
20. Sakorafas GH, Milingos D, Peros G. Asymptomatic Cholelithiasis: is cholecystectomy really needed? A critical reappraisal 15 years after the introduc­tion of laparoscopic cholecystectomy. Dig Dis Sci. 2007;52:1313–25.
21. Lowenfels AB, Walker AM, Althaus DP, Townsend G, Domellöf L.Gallstone growth, size, and risk of gall-
128
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
O. N. Dilek and N. Acar
bladder cancer: an interracial study. Int J Epidemiol. 1989;18:50–4.
22. Patino JF, Quintero GA.Asymptomatic cholelithiasis revisited. World J Surg. 1998;22:1119–24.
23. Freeman MH, Mullen MG, Friel CM. The progres­sion of cholelithiasis to gallstone ileus: do large gallstones warrant surgery? J Gastrointest Surg. 2016;20(6):1278–80.
24. Seretis C, Lagoudianakis E, Gemenetzis G, Seretis F, Pappas A, Gourgiotis S. Metaplastic changes in chronic cholecystitis: implications for early diagno­sis and surgical intervention to prevent the gallblad­der metaplasia-dysplasia-carcinoma sequence. J Clin Med Res. 2014;6(1):26–9.
25. Csendes A, Becerra M, Rojas J, Medina E.Number and size of stones in patients with asymptomatic and symptomatic gallstones and gallbladder carcinoma: a prospective study of 592 cases. J Gastrointest Surg. 2000;4(5):481–5.
26. Choi SY, Kim TS, Kim HJ, Park JH, Park DI, Cho YK, et al. Is it necessary to perform prophylactic cholecystectomy for asymptomatic subjects with gallbladder polyps and gallstones? J Gastroenterol Hepatol. 2010;25(6):1099–104.
27. Alvi AR, Siddiqui NA, Zafar H.Risk factors of gall­bladder cancer in Karachi—a case-control study. World J Surg Oncol. 2011;9:164.
28. Frossard JL, Morel PM. Detection and manage­ment of bile duct stones. Gastrointest Endosc. 2010;72(4):808–16.
29. Boerma D, Rauws EA, Keulemans YC, Janssen IM, Bolwerk CJ, Timmer R, et al. Wait-and-see policy or laparoscopic cholecystectomy after endoscopic sphincterotomy for bile-duct stones: a randomised trial. Lancet. 2002;360(9335):761–5.
30. Nakai Y, Isayama H, Tsujino T, Hamada T, Kogure H, Takahara N, etal. Cholecystectomy after endoscopic papillary balloon dilation for bile duct stones reduced late biliary complications: a propensity score-based cohort analysis. Surg Endosc. 2016;30:3014–20.
31. Cui ML, Cho JH, Kim TN. Long-term follow-up study of gallbladder in situ after endoscopic common duct stone removal in Korean patients. Surg Endosc. 2013;27:1711–6.
32. Schreurs WH, Vles WJ, Stuifbergen WH, Oostvogel HJ. Endoscopic management of common bile duct stones leaving the gallbladder in situ. A cohort study with long-term follow-up. Dig Surg. 2004;21(1):60– 4; discussion 65.
33. Yasui T, Takahata S, Kono H, Nagayoshi Y, Mori Y, Tsutsumi K, et al. Is cholecystectomy necessary after endoscopic treatment of bile duct stones in patients older than 80 years of age? J Gastroenterol. 2012;47(1):65–70.
34. Portincasa P, Molina-Molina E, Garruti G, Wang DQ.Critical care aspects of gallstone disease. J Crit Care Med (Targu Mures). 2019;5(1):6–18.
35. Uhl W, Muller CA, Krahenbuhl L, Schmid SW, Scholzel S, Buchler MW.Acute gallstone pancreati-
tis: timing of laparoscopic cholecystectomy in mild and severe disease. Surg Endosc. 1999;13:1070–6.
36. Stevens CL, Abbas SM, Watters DA. How does cholecystectomy inuence recurrence of idio­pathic acute pancreatitis? J Gastrointest Surg. 2016;20(12):1997–2001.
37. Räty S, Pulkkinen J, Nordback I, Sand J, Victorzon M, Grönroos J, etal. Can laparoscopic cholecystectomy prevent recurrent idiopathic acute pancreatitis? A prospective randomized multicenter trial. Ann Surg. 2015;262(5):736–41.
38. European Association for the Study of the Liver (EASL). EASL clinical practice guidelines on the prevention, diagnosis and treatment of gallstones. J Hepatol. 2016;65:146–81.
39. Iolascon A, Andolfo I, Barcellini W, Corcione F, Garçon L, De Franceschi L, etal. Recommendations regarding splenectomy in hereditary hemolytic ane­mias. Haematologica. 2017;102(8):1304–13.
40. Al-Mulhim AS, Al-Mulhim AA. Laparoscopic cholecystectomy in 427 adults with sickle cell dis­ease: a single-center experience. Surg Endosc. 2009;23:1599–602.
41. Muroni M, Loi V, Lionnet F, Girot R, Houry S.Prophylactic laparoscopic cholecystectomy in adult sickle cell disease patients with cholelithiasis: a pro­spective cohort study. Int J Surg. 2015;22:62–6.
42. Poddar U. Gallstone disease in children. Indian Pediatr. 2010;47(11):945–53.
43. Feretis CB, Legakis NC, Apostolidis NS, Katergiannakis VA, Philippakis MG. Prophylactic cholecystectomy during splenectomy for beta thalas­semia homozygous in Greece. Surg Gynecol Obstet. 1985;160(1):9–12.
44. Dray X, Joly F, Reijasse D, Attar A, Alves A, Panis Y, etal. Incidence, risk factors, and complications of cholelithiasis in patients with home parenteral nutri­tion. J Am Coll Surg. 2007;204:13–21.
45. Thompson JS. The role of prophylactic cholecys­tectomy in the short-bowel syndrome. Arch Surg. 1996;131(5):556–60.
46. Appleton ND, Lal S, Carlson GL, Shaw S, Stevens P, Peristerakis I, etal. Cholelithiasis and related mor­bidity in chronic intestinal failure: a longitudinal cohort study from a national specialized Centre. J Gastrointest Surg. 2019;23(10):2002–6.
47. Norlén O, Hessman O, Stålberg P, Akerström G, Hellman P. Prophylactic cholecystectomy in midgut carcinoid patients. World J Surg. 2010;34(6):1361–7.
48. Brighi N, Panzuto F, Modica R, Gelsomino F, Albertelli M, Pusceddu S, etal. Biliary stone disease in patients with neuroendocrine tumors treated with somatostatin analogs: a multicenter study. Oncologist. 2020;25(3):259–65.
49. Michielsen PP, Fierens H, Van Maercke YM.Drug­induced gallbladder disease. Incidence, aetiology and management. Drug Saf. 1992;7(1):32–45.
50. Ottery FD, Scupham RK, Weese JL.Chemical cho­lecystitis after intrahepatic chemotherapy. The case
11 Prophylactic Surgery forGallbladder andBiliary Tract Pathologies
129
for prophylactic cholecystectomy during pump place­ment. Dis Colon Rectum. 1986;29(3):187–90.
51. Lafon PC, Reed K, Rosenthal D.Acute cholecystitis associated with hepatic arterial infusion of oxuri­dine. Am J Surg. 1985;150(6):687–9.
52. Carrasco CH, Freeny PC, Chuang VP, Wallace S. Chemical cholecystitis associated with hepatic artery infusion chemotherapy. AJR Am J Roentgenol. 1983;141(4):703–6.
53. Graham SM, Flowers JL, Schweitzer E, Bartlett ST, Imbembo AL.The utility of prophylactic laparoscopic cholecystectomy in transplant candidates. Am J Surg. 1995;169(1):44–9.
54. Kao LS, Flowers C, Flum DR.Prophylactic cholecys­tectomy in transplant patients: a decision analysis. J Gastrointest Surg. 2005;9:965–72.
55. Kilic A, Sheer A, Shah AS, Russell SD, Gourin CG, Lidor AO.Outcomes of cholecystectomy in US heart transplant recipients. Ann Surg. 2013;258(2):312–7.
56. Jackson T, Treleaven D, Arlen D, D’Sa A, Lambert K, Birch DW.Management of asymptomatic cholelithia­sis for patients awaiting renal transplantation. Surg Endosc. 2005;19(4):510–3.
57. Moray G, Başaran O, Karakayali H, Yağmurdur MC, Bilgin N, Haberal M. Evaluation and treatment of biliary lithiasis in renal transplantation candidates. Transplant Proc. 2003;35(7):2712–3.
58. Sutariya V, Tank A.An audit of laparoscopic chole­cystectomy in renal transplant patients. PC can be per­formed safely both in recipients and candidates. Ann Med Health Sci Res. 2014;4(1):48–50.
59. Amstutz S, Michel JM, Kopp S, Egger B.Potential benets of prophylactic cholecystectomy in patients undergoing bariatric bypass surgery. Obes Surg. 2015;25(11):2054–60.
60. Shiffman ML, Shamburek RD, Schwartz CC, Sugerman HJ, Kellum JM, Moore EW, et al. Gallbladder mucin, arachidonic acid, and bile lipids in patients who develop gallstones during weight reduc­tion. Gastroenterology. 1993;105(4):1200–8.
61. Sneineh MA, Harel L, Elnasasra A, Razin H, Rotmensh A, Moscovici S, etal. Increased incidence of symptomatic cholelithiasis after bariatric roux-En­Y gastric bypass and previous bariatric surgery: a sin­gle center experience. Obes Surg. 2020;30(3):846–50.
62. Morais M, Faria G, Preto J, Costa-Maia J.Gallstones and bariatric surgery: to treat or not to treat? World J Surg. 2016;40:2904–10.
63. Raziel A, Sakran N, Szold A, Goitein D.Concomitant cholecystectomy during laparoscopic sleeve gastrec­tomy. Surg Endosc. 2015;29(9):2789–93.
64. Chen J, Tsai M, Chen C, Lee HM, Cheng CF, Chiu YT, etal. Bariatric surgery did not increase the risk of gallstone disease in obese patients: a comprehensive cohort study. Obes Surg. 2019;29:464–73.
65. Tsirline VB, Keilani ZM, El Djouzi S, Phillips RC, Kuwada TS, Gersin K, etal. How frequently and when do patients undergo cholecystectomy after bariatric surgery? Surg Obes Relat Dis. 2014;10(2):313–21.
66. Yardimci S, Coskun M, Demircioglu S, Erdim A, Cingi A.Is concomitant cholecystectomy necessary for asymptomatic cholelithiasis during laparoscopic sleeve gastrectomy? Obes Surg. 2018;28:469–73.
67. Worni M, Guller U, Shah A, Gandhi M, Shah J, Rajgor D, et al. Cholecystectomy concomitant with laparoscopic gastric bypass: a trend analysis of the nationwide inpatient sample from 2001 to 2008. Obes Surg. 2012;22(2):220–9.
68. Hussain A, El-Hasani S.Potential benets of prophy­lactic cholecystectomy in patients undergoing bariat­ric bypass surgery. Obes Surg. 2016;26(4):865.
69. Mazlum M, Dilek FH, Yener AN, Tokyol C, Aktepe F, Dilek ON.Prole of gallbladder diseases diagnosed at Afyon Kocatepe university: a retrospective study. Turk Patoloji Derg. 2011;27(1):23–30.
70. Dilek ON, Karasu Ş, Dilek FH.Diagnosis and treat­ment of gallbladder polyps; current perspectives. Euroasian J Hepatogastroenterol. 2019;9(1):40–8.
71. Wiles R, Thoeni RF, Barbu ST, Vashist YK, Rafaelsen SR, Dewhurst C, et al. Management and follow-up of gallbladder polyps: joint guidelines between the European Society of Gastrointestinal and Abdominal Radiology (ESGAR), European Association for Endoscopic Surgery and other interventional tech­niques (EAES), International Society of Digestive Surgery—European Federation (EFISDS) and European Society of Gastrointestinal Endoscopy (ESGE). Eur Radiol. 2017;27:3856–66.
72. Chijiiwa K, Tanaka M. Polypoid lesion of the gall­bladder: indications of carcinoma and outcome after surgery for malignant polypoid lesion. Int Surg. 1994;79:106–9.
73. Miyazaki M, Takada T, Miyakawa S, Tsukada K, Nagino M, Kondo S, et al. Risk factors for biliary tract and ampullary carcinomas and prophylactic sur­gery for these factors. J Hepatobiliary Pancreat Surg. 2008;15(1):15–24.
74. Vogel T, Schumacher V, Saleh A, Trojan J, Möslein G.Extraintestinal polyps in Peutz-Jeghers syndrome: presentation of four cases and review of the litera­ture. Deutsche Peutz-Jeghers-Studiengruppe. Int J Colorectal Dis. 2000;15(2):118–23.
75. Bonatti M, Vezzali N, Lombardo F, Ferro F, Zamboni G, Tauber M, et al. Gallbladder adenomyomatosis: imaging ndings, tricks and pitfalls. Insights Imaging. 2017;8:243–53.
76. National Comprehensive Cancer Network. Hepatobiliary cancers (Version 2.2020). https://www.
nccn.org/professionals/physician_gls/pdf/hepatobili­ary.pdf. Accessed 9 May 2020.
77. Khan ZS, Livingston EH, Huerta S.Reassessing the need for prophylactic surgery in patients with porce­lain gallbladder: case series and systematic review of the literature. Arch Surg. 2011;146(10):1143–7.
78. Towgh S, McFadden DW, Cortina GR, Thompson JE Jr, Tompkins RK, Chandler C, etal. Porcelain gall­bladder is not associated with gallbladder carcinoma. Am Surg. 2001;67(1):7–10.
130
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
O. N. Dilek and N. Acar
79. Chen GL, Akmal Y, DiFronzo AL, Vuong B, O’Connor V. Porcelain gallbladder: no longer an indication for prophylactic cholecystectomy. Am Surg. 2015;81(10):936–40.
80. Jones MW, Weir CB, Ferguson T. Porcelain gall­bladder. StatPearls (Internet).
nih.gov/pubmed/30085521
https://www.ncbi.nlm.
. Accessed 19 May 2020.
81. Bangash M, Alvi AR, Shahzad N, Shariff AH, Gill RC.Factors associated with premalignant epithelial changes in chronic calculous cholecystitis: a case– control study. World J Surg. 2018;42:1701–5.
82. Baba H, Wakabayashi M, Oba A, Tsubomoto T, Nakamura H, Sanada T, et al. Primary papillary hyperplasia of the gallbladder mimicking gallblad­der cancer. Int Surg. 2014;99(3):247–51.
83. Hyvärinen I, Hukkinen M, Kivisaari R, Parviainen H, Nordin A, Pakarinen MP.Increased prevalence of pancreaticobiliary maljunction in biliary malignan­cies. Scand J Surg. 2019;108(4):285–90.
84. Morine Y, Shiamda M, Takamatsu H, Araida T, Endo I, Kubota M, etal. Clinical features of pancreatico­biliary maljunction: update analysis of 2nd Japan­nationwide survey. J Hepatobiliary Pancreat Surg. 2013;20:472–80.
85. Kamisawa T, Kuruma S, Chiba K, Tabata T, Koizumi S, Kikuyama M. Biliary carcinogenesis in pancreaticobiliary maljunction. J Gastroenterol. 2017;52:158–63.
86. Takuma K, Kamisawa T, Tabata T, Hara S, Kuruma S, Inaba Y, et al. Importance of early diagnosis of pancreaticobiliary maljunction without biliary dila­tation. World J Gastroenterol. 2012;18(26):3409–14.
87. Miyazaki M, Yoshitomi H, Miyakawa S, Uesaka K, Unno M, Endo I, etal. Clinical practice guidelines for the management of biliary tract cancers 2015. J Hepatobiliary Pancreat Sci. 2015;22(4):249–73.
88. Liang TJ, Liu SI, Chen YC, Chang PM, Huang WC, Chang HT, et al. Analysis of gallstone dis­ease after gastric cancer surgery. Gastric Cancer. 2017;20:895–903.
89. Wu CC, Chen CY, Wu TC, Iiu TJ, P’Eng PK.Cholelithiasis and cholecystitis after gastrectomy for gastric carcinoma: a comparison of lymphade­nectomy of varying extent. Hepatogastroenterology. 1995;42:867–72.
90. Fukagawa T, Katai H, Saka M, Morita S, Sano T, Sasako M.Gallstone formation after gastric Cancer surgery. J Gastrointest Surg. 2009;13:886–9.
91. Kodama I, Yoshida C, Kofuji K, Ohta J, Aoyagi K, Takeda J. Gallstones and gallbladder disor­der after gastrectomy for gastric cancer. Int Surg. 1996;81:36–9.
92. Hauters P, de Neve de Roden A, Pourbaix A, Aupaix F, Coumans P, Therasse G. Cholelithiasis: a seri­ous complication after total gastrectomy. Br J Surg. 1988;75:899–900.
93. Kobayashi T, Hisanaga M, Kanehiro H, Yamada Y, Ko S, Nakajima Y.Analysis of risk factors for the development of gallstones after gastrectomy. Br J Surg. 2005;92:1399–403.
94. Bencini L, Marchet A, Aleri S, Rosa F, Verlato G, Marrelli D, etal. The Cholegas trial: long-term results of prophylactic cholecystectomy during gas­trectomy for cancer-a randomized-controlled trial. Gastric Cancer. 2019;22:632–9.
95. Cavallin F, Scarpa M, Cagol M, Aleri R, Ruol A, Chiarion Sileni V, et al. Cholecystectomy during esophagectomy is safe but unnecessary. Acta Chir Belg. 2020;120(1):35–41.
96. Gillen S, Michalski CW, Schuster T, Feith M, Friess H, Kleeff J. Simultaneous/incidental cholecystec­tomy during gastric/esophageal resection: system­atic analysis of risks and benets. World J Surg. 2010;34:1008–14.
97. Miftode SV, Troja A, El-Sourani N, Raab HR, Antolovic D.Simultaneous cholecystectomy during gastric and oesophageal resection: a retrospective analysis and critical review of literature. Int J Surg. 2014;12:1357–9.
98. Goet JC, Beelen EMJ, Biermann KE, Gijsbers AH, Schouten WR, van der Woude CJ, et al. Cholecystectomy risk in Crohn’s disease patients after ileal resection: a long-term Nationwide Cohort Study. J Gastrointest Surg. 2019;23(9):1840–7.
99. Koutroumpakis F, Lodhi M, Ahsan M, Ramos Rivers C, Schwartz M, Hashash JG, et al. The impact of cholecystectomy on long-term disease outcomes and quality of life in patients with Crohn’s disease. Inamm Bowel Dis. 2020;
https://doi.org/10.1093/
ibd/izaa076. [Epub ahead of print].
100. Pezzolla F, Lorusso D, Guerra V, Giorgio I.Asymptomatic gallstones. What to do in patients undergoing colonic surgery for cancer? Acta Chir Belg. 1993;93(4):154–7.
101. Paul J, Gessner F, Wechsler JG, Kuhn K, Orth K, Ditschuneit H.Increased incidence of gallstones and prior cholecystectomy in patients with large bowel cancer. Am J Gastroenterol. 1992;87(9):1120–4.
102. Nogueira L, Freedman ND, Engels EA, Warren JL, Castro F, Koshiol J. Gallstones, cholecystec­tomy, and risk of digestive system cancers. Am J Epidemiol. 2014;179(6):731–9.
103. Moszkowicz D, Mariani A, Trésallet C, Menegaux F.Ischemic colitis: the ABCs of diagnosis and surgi­cal management. J Visc Surg. 2013;150(1):19–28.
104. Parente F, Pastore L, Bargiggia S, Cucino C, Greco S, Molteni M, etal. Incidence and risk factors for gallstones in patients with inammatory bowel disease: a large case-control study. Hepatology. 2007;45(5):1267–74.
105. Ha JH, Park YS, Seon CS, Son BK, Ahn SB, Jo YK, et al. Increased risk of asymptomatic gall­stones in patients with ulcerative colitis. Intest Res. 2015;13:122–7.
106. Jeong YH, Kim KO, Lee HC, Sohn SH, Lee JW, Lee SH, et al. Gallstone prevalence and risk factors in patients with ulcerative colitis in Korean population. Medicine (Baltimore). 2017;96(31):e7653.
107. Mark-Christensen A, Brandsborg S, Laurberg S, Johansen N, Pachler JH, Thorlacius-Ussing O, etal.
11 Prophylactic Surgery forGallbladder andBiliary Tract Pathologies
131
Increased risk of gallstone disease following col­ectomy for ulcerative colitis. Am J Gastroenterol. 2017;112(3):473–8.
108. Kaibori M, Kubo S, Nagano H, Hayashi M, Nakai T, Ishizaki M, et al. Higher complication rate in hepatocellular carcinoma patients undergoing pro­phylactic cholecystectomy with curative hepatic resection. Hepatogastroenterology. 2014;61(135): 2028–34.
109. Coccolini F, Coimbra R, Ordonez C, Kluger Y, Vega F, Moore EE, etal. Liver trauma: WSES 2020 guide­lines. World J Emerg Surg. 2020;15(1):24.
110. Auer RC, Sivajohanathan D, Biagi J, Conner J, Kennedy E, May T. Indications for hyperthermic intraperitoneal chemotherapy with cytoreduc­tive surgery: a systematic review. Eur J Cancer. 2020;127:76–95.
111. Liakou CG, Akrivos N, Kumar B, Duncan TJ, Turnbull HL, Nieto JJ, et al. Cholecystectomy as part of cytoreductive surgery for advanced ovarian cancer: perioperative outcomes. Anticancer Res. 2020;40(4):2331–6.
112. Charokopos N, Antonitsis P, Spanos C, Rouska E, Spanos P. Concomitant cholecystectomy and open­heart surgery. Surg Today. 2007;37(8):638–41.
113. Cachoeira E, Rivas A, Gabrielli C.Anatomic varia­tions of extrahepatic bile duct and evaluation of the length of ducts composing the Cystohepatic triangle. Int J Morphol. 2012;30(1):279–83.
114. Khayat MF, Al-Amoodi MS, Aldaqal SM, Sibiany A.Abnormal anatomical variations of extra-hepatic biliary tract, and their relation to biliary tract inju­ries and stones formation. Gastroenterology Res. 2014;7(1):12–6.
115. Dundaraddy R, Mahesh G.Study of variations in the extrahepatic biliary system. Biom J. 2012;3(03):1–3.
116. Ersöz N, Öztaş M, Can MF, Günal A, Özerhan İH, Yağcı G, etal. Duplication cyst of gallbladder. Case report. J Surg Arts. 2013;6(2):64–6.
117. Darnis B, Mohkam K, Cauchy F, Cazauran JB, Bancel B, Rode A, etal. A systematic review of the anatomical ndings of multiple gallbladders. HPB (Oxford). 2018;20(11):985–91.
118. Alicioglu B.An incidental case of triple gallbladder. World J Gastroenterol. 2007;13(13):2004–6.
119. Alam MT, Qaiser B, Jamaluddin M, Abbas Hussain SM. Bilobed gallbladder. J Coll Physicians Surg Pak. 2011;21(6):367–8.
120. Wong HYF, Lee KH. The hourglass gallbladder. Abdom Radiol. 2018;43:1268–9.
121. Dongol S, Thompson CN, Clare S, Nga TV, Duy PT, Karkey A, et al. The microbiological and clinical characteristics of invasive salmonella in gallblad­ders from cholecystectomy patients in Kathmandu, Nepal. PLoS One. 2012;7(10):e47342.
122. Vagholkar K, Pawanarkar A, Iyengar M, Vagholkar S.Chronic Salmonella typhi carrier state: a precursor to gall bladder cancer. Int Surg J. 2016;3(2):464–7.
123. Gonzalez-Escobedo G, Marshall JM, Gunn JS.Chronic and acute infection of the gall bladder
by Salmonella Typhi: understanding the carrier state. Nat Rev Microbiol. 2011;9(1):9–14.
124. Funabiki T, Matsubara T, Miyakawa S, Ishihara S.Pancreaticobiliary maljunction and carcinogenesis to biliary and pancreatic malignancy. Langenbecks Arch Surg. 2009;394:159–69.
125. Takayashiki T, Miyazaki M, Kato A, Ito H, Nakagawa K, Ambiru S, et al. Double cancer of gallbladder and bile duct associated with anomalous junction of the pancreaticobiliary ductal system. Hepatogastroenterology. 2002;49:109–12.
126. Hara H, Morita S, Ishibashi T, Sako S, Dohi T, Otani M, et al. Studies on biliary tract carcinoma in the case with pancreaticobiliary maljunction. Hepatogastroenterology. 2002;49:104–8.
127. Jabłońska B. Biliary cysts: etiology, diagno­sis and management. World J Gastroenterol. 2012;18(35):4801–10.
128. Søreide K, Søreide JA. Bile duct cyst as pre­cursor to biliary tract cancer. Ann Surg Oncol. 2007;14(3):1200–11.
129. Ten Hove A, de Meijer VE, Hulscher JBF, de Kleine RHJ. Meta-analysis of risk of developing malig­nancy in congenital choledochal malformation. Br J Surg. 2018;105(5):482–90.
130. Todani T, Watanabe Y, Narusue M, Tabuchi K, Okajima K.Congenital bile duct cysts. Classication, operative procedures, and review of thirty-seven cases including cancer arising from choledochal cyst. Am J Surg. 1977;134(2):263–9.
131. Machado NO, Chopra PJ, Al-Zadjali A, Younas S. Choledochal cyst in adults: etiopathogenesis, presentation, management, and outcome-case series and review. Gastroenterol Res Pract. 2015;2015:
602591.
132. Sibulesky L, Nguyen J, Patel T.Preneoplastic condi­tions underlying bile duct cancer. Langenbecks Arch Surg. 2012;397:861–7.
133. Singham J, Yoshida EM, Scudamore CH. Choledochal cysts. Part 3 of 3: management. Can J Surg. 2010;53(1):51–6.
134. Lee SE, Jang JY, Lee YJ, Choi DW, Lee WJ, Cho BH, et al. Choledochal cyst and associated malig­nant tumors in adults: a multicenter survey in South Korea. Arch Surg. 2011;146(10):1178–84.
135. Burak K, Angulo P, Pasha TM, Egan K, Petz J, Lindor KD. Incidence and risk factors for cholan­giocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol. 2004;99(3):523–6.
136. Yoshida N, Aoyagi T, Kimura Y, Naito Y, Izuwa A, Mizoguchi K, etal. A rare case of symptomatic grossly visible biliary intraepithelial neoplasia mim­icking cholangiocarcinoma. World J Surg Oncol. 2019;17(1):191.
137. Hucl T. Precursors to cholangiocarcinoma. Gastroenterol Res Pract. 2019;2019:1389289.
138. Wu X, Li B, Zheng C, Chang X, Zhang T, He X, etal. Intraductal papillary neoplasm of the bile duct: a single-center retrospective study. J Int Med Res. 2018;46(10):4258–68.
132
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
O. N. Dilek and N. Acar
139. Chikamoto A, Tsuji T, Nakahara O, Sakamoto Y, Ikuta Y, Tanaka H, et al. Cancer cells spread through lymph vessels in the submucosal layer of the common bile duct in gallbladder carcinoma. J Hepatobiliary Pancreat Surg. 2009;16:557–61.
140. Wiggers JK, Groot Koerkamp B, Ovadia Z, Busch OR, Gouma DJ, van Gulik TM.Patterns of recur­rence after resection of gallbladder cancer with­out routine extrahepatic bile duct resection. HPB (Oxford). 2014;16(7):635–40.
141. D’Angelica M, Dalal KM, DeMatteo RP, Fong Y, Blumgart LH, Jarnagin WR.Analysis of the extent of resection for adenocarcinoma of the gallbladder. Ann Surg Oncol. 2009;16:806–16.
142. Sakamoto Y, Kosuge T, Shimada K, Sano T, Hibi T, Yamamoto J, etal. Clinical signicance of extrahe­patic bile duct resection for advanced gallbladder cancer. J Surg Oncol. 2006;94(4):298–306.
143. Igami T, Ebata T, Yokoyama Y, Sugawara G, Mizuno T, Yamaguchi J, etal. Combined extrahepatic bile duct resection for locally advanced gallbladder carci­noma: does it work? World J Surg. 2015;39:1810–7.
144. Shimizu Y, Ohtsuka M, Ito H, Kimura F, Shimizu H, Togawa A, etal. Should the extrahepatic bile duct be resected for locally advanced gallbladder cancer? Surgery. 2004;136(5):1012–8.
145. Ouchi K, Mikuni J, Kakugawa Y, Organizing Committee, The 30th Annual Congress of the Japanese Society of Biliary Surgery. Laparoscopic cholecystectomy for gallbladder carcinoma: results of a Japanese survey of 498 patients. J Hepatobiliary Pancreat Surg. 2002;9:256–60.
146. Paolucci V, Schaeff B, Schneider M, Gutt C.Tumor seeding following laparoscopy: international survey. World J Surg. 1999;23:989–95.
147. Wakai T, Shirai Y, Yokoyama N, Ajioka Y, Watanabe H, Hatakeyama K.Depth of subserosal invasion pre­dicts long-term survival after resection in patients with T2 gallbladder carcinoma. Ann Surg Oncol. 2003;10:447–54.
148. Erlichman J, Loomes KM.Biliary atresia [Internet]. Waltham, MA: UpToDate. https://www.uptodate.
com/contents/biliary- atresia. Accessed 30 May
2020.
149. Davenport M, Ure BM, Petersen C, Kobayashi H.Surgery for biliary atresia—is there a European consensus? Eur J Pediatr Surg. 2007;17:180.
150. Schreiber RA, Barker CC, Roberts EA, Martin SR.Biliary atresia in Canada: the effect of Centre caseload experience on outcome. Canadian Pediatric Hepatology Research Group. J Pediatr Gastroenterol Nutr. 2010;51(1):61–5.
Prophylactic Splenectomy
NuruYusifogluBayramov, RuslanAydınogluMammadov, andFarahAlqızıGahramanova
12
12.1 Introduction
Splenectomy is performed for the palliative and radical treatment of primary splenic diseases, extra­splenic diseases, and splenomegaly. The rst sple­nectomy was performed by Andirano Zaccarello in 1549 on a woman with massive splenomegaly. The rst successful splenectomy for hematological disorder was performed by Quittenbaum in 1826 [1]. In 1893, Reigner reported the rst successful splenectomy for splenic rupture [2]. Since the rst report of laparoscopic splenectomy by Delaitre and Maignen in 1991, laparoscopic approach has become a standard procedure for elective splenec­tomy [3]. The rst laparoscopic splenectomy in children was performed in 1993 by Tulman [4].
12.2 Splenectomy
Classically, splenectomy is performed for ve main purposes: to stop bleeding, to extend the lifespan of the pathologic blood cells, in the treatment of the complications of splenomegaly, to remove the splenic masses and sources of dis­eases located in the spleen, and to establish the diagnosis. Indications for splenectomy can be divided into three groups: primary, secondary,
N. Y. Bayramov · R. A. Mammadov (*) F. A. Gahramanova Department of General Surgery and Transplantology, Azerbaijan Medical University, Baku, Azerbaijan
and controversial (Table12.1). The primary indi­cations consist of the cases, in which there is no other alternative; splenectomy is the only effec­tive treatment method. In secondary indications, splenectomy is an effective treatment method, but there are also other alternatives. In these cases, splenectomy should be selectively performed when other treatment methods are ineffective. Controversial group indicates the cases in which the effectiveness of splenectomy is not always high and splenectomy is considered as last resort.
The prophylactic splenectomy is to remove healthy or uncomplicated enlarged spleen to alleviate the clinical course of splenic and extra­splenic diseases and to prevent disease recur­rence and complications of splenomegaly.
Indications for prophylactic splenectomy are not dened precisely and quite controversial. The splenectomy indications are as follows:
– Splenic echinococcosis. – Gastric cancer. – Cytoreductive surgery for ovarian cancer. – HCC treatment. – LDLT (living donor liver transplantation). – Distal pancreatectomy. – Chronic pancreatitis. – Wandering spleen (mobile spleen). – Splenic vein thrombosis (Banti syndrome). – Hematological diseases. – Sickle cell anemia. – Splenic artery aneurysm. – Cirrhosis.
© The Author(s), under exclusive license to Springer Nature Switzerland AG 2021 O. N. Dilek et al. (eds.), Prophylactic Surgery, https://doi.org/10.1007/978-3-030-66853-2_12
133
Соседние файлы в папке Библиотека им академика М.И. Перельмана
Помощь Обратная связь Вопросы и предложения Пользовательское соглашение Политика конфиденциальности